Aurobindo Pharma

₹1257.1 -5.3 | 0.4%

WEBSITE BSE:524804 NSE : AUROB.PHARMA 26 Dec, 16:01

Market Cap ₹73010 Cr.

Stock P/E 23.0

P/B 3.7

Current Price ₹1257.1

Book Value ₹ 338.4

Face Value 1

52W High ₹1592.6

Dividend Yield 0.36%

52W Low ₹ 959.1

Edit Ratio

Aurobindo Pharma Research see more...

Overview Inc. Year: 1986Industry: Pharmaceuticals & Drugs

Aurobindo Pharma Ltd is an India-based pharmaceutical company. The Company develops, manufactures and distributes generic pharmaceuticals, branded specially prescribed drugs and active pharmaceutical elements. Its product portfolio is spread over seven therapeutic/product areas comprising central nervous structures (CNS), anti-retroviral, cardiovascular (CVS), antibiotics, gastroenterological, anti-diabetics and anti-allergic. It is engaged in growing a variety of oncology and hormonal products. It is growing topical as well as transdermal products within the dermatology therapeutic section. It is likewise developing approximately three depot injections based on the microsphere and nano-suspension structures. The Company is advertising its merchandise globally around 150 countries. The Company's subsidiaries consist of APL Healthcare Ltd, Auronext Pharma Private Ltd, Auro Peptides Ltd, APL Pharma Thai Ltd and Aurolife Pharma LLC, amongst others.

Aurobindo Pharma Share Price

New

Volume

Price

Price: NSE50 DMA200 DMAVolume

Quarterly Price

Quarterly Monthly

Show Value Show %

Peer Comparison

Aurobindo Pharma Quarterly Results

#(Fig in Cr.)
Net Sales
Other Income
Total Income
Total Expenditure
Operating Profit
Interest
Depreciation
Exceptional Income / Expenses
Profit Before Tax
Provision for Tax
Profit After Tax
Adjustments
Profit After Adjustments
Adjusted Earnings Per Share

Aurobindo Pharma Profit & Loss

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Net Sales	7111	8095	9166	9607	10270	12258	13371	15824	11287	8457	10646
Other Income	75	67	188	136	81	199	389	590	689	444	616
Total Income	7186	8162	9355	9743	10351	12457	13760	16414	11976	8901	11262
Total Expenditure	5191	5845	6714	7233	7600	9849	10673	11704	9832	6952	8422
Operating Profit	1994	2318	2640	2510	2751	2609	3087	4710	2144	1949	2840
Interest	289	132	229	45	53	231	243	29	17	75	183
Depreciation	186	245	263	286	355	413	473	488	415	243	255
Exceptional Income / Expenses	0	0	0	0	0	0	0	0	-75	0	0
Profit Before Tax	1519	1940	2148	2179	2343	1965	2370	4193	1637	1631	2403
Provision for Tax	347	424	521	472	530	435	493	1080	183	389	503
Profit After Tax	1172	1516	1627	1707	1813	1530	1877	3113	1455	1242	1900
Adjustments	0	0	0	0	0	0	0	0	0	-15	54
Profit After Adjustments	1172	1516	1627	1707	1813	1530	1877	3113	1455	1227	1954
Adjusted Earnings Per Share	20.1	26	27.8	29.1	30.9	26.1	32	53.1	24.8	21.2	32.4

Growth Rates

#	1 Year	3 Year	5 Year	10 Year
Sales CAGR	26%	-12%	-3%	4%
Operating Profit CAGR	46%	-16%	2%	4%
PAT CAGR	53%	-15%	4%	5%

#	1 Year	3 Year	5 Year	10 Year
Share Price CAGR	18%	20%	22%	9%
ROE Average	10%	9%	13%	19%
ROCE Average	12%	9%	13%	18%

Aurobindo Pharma Balance Sheet

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Shareholder's Funds	4012	5360	6866	8436	9983	11351	13053	15925	17117	18034	19723
Minority's Interest	0	0	0	0	0	0	0	0	0	0	0
Borrowings	1032	687	335	119	0	0	0	0	0	0	0
Other Non-Current Liabilities	214	233	14	21	57	54	139	1412	4566	3138	3400
Total Current Liabilities	3317	3946	5344	4447	5754	6736	6372	6757	4181	6993	5747
Total Liabilities	8576	10226	12559	13023	15794	18141	19564	24093	25865	28166	28869
Fixed Assets	1938	2190	2568	3212	3393	4150	4418	4472	3586	3688	2419
Other Non-Current Assets	1556	1668	2216	2908	3420	3583	3858	7285	12444	14199	18709
Total Current Assets	5081	6368	7775	6903	8981	10408	11288	12336	9835	10280	7741
Total Assets	8576	10226	12559	13023	15794	18141	19564	24093	25865	28166	28869

Aurobindo Pharma Cash Flow

#(Fig in Cr.)	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Opening Cash & Cash Equivalents	115	10	-26	284	-132	240	69	67	384	51	357
Cash Flow from Operating Activities	328	590	1185	2457	922	530	2201	2995	3727	1816	1715
Cash Flow from Investing Activities	-401	-624	-1390	-1542	-991	-1297	-952	-2649	-1614	-3458	-160
Cash Flow from Financing Activities	-31	35	515	-1329	440	599	-1255	-28	-2448	1719	-1837
Net Cash Inflow / Outflow	-105	1	310	-414	371	-168	-5	318	-334	78	-282
Closing Cash & Cash Equivalent	10	11	284	-130	240	69	67	384	48	357	83

Aurobindo Pharma Ratios

#	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Earnings Per Share (Rs)	20.1	25.96	27.8	29.13	30.94	26.11	32.03	53.13	24.83	21.2	32.43
CEPS(Rs)	23.29	30.16	32.29	34.01	37	33.16	40.11	61.46	31.92	25.35	36.78
DPS(Rs)	3	4.5	2.5	2.5	2.5	2.5	3	4	9	3	4.5
Book NAV/Share(Rs)	68.82	91.77	117.3	143.99	170.38	193.73	222.78	271.8	292.15	307.8	336.62
Core EBITDA Margin(%)	26.4	27.29	26.3	24.27	25.91	19.56	20.11	25.95	12.82	17.76	20.86
EBIT Margin(%)	24.88	25.14	25.5	22.73	23.25	17.83	19.48	26.59	14.58	20.13	24.25
Pre Tax Margin(%)	20.9	23.53	23.04	22.27	22.74	15.95	17.67	26.41	14.43	19.25	22.53
PAT Margin (%)	16.12	18.39	17.45	17.45	17.59	12.42	13.99	19.61	12.82	14.66	17.82
Cash Profit Margin (%)	18.68	21.36	20.27	20.38	21.04	15.78	17.52	22.68	16.48	17.53	20.21
ROA(%)	15.22	16.13	14.28	13.34	12.58	9.02	9.96	14.26	5.82	4.6	6.66
ROE(%)	33.72	32.36	26.61	22.31	19.68	14.34	15.38	21.49	8.81	7.07	10.06
ROCE(%)	28.57	26.6	24.16	19.75	19.02	14.85	16.01	23.03	8.52	8.3	11.56
Receivable days	118.01	147.84	158.37	152.15	145.99	143.76	149.89	134.65	159.2	183.77	142.68
Inventory Days	78.92	85.37	89.59	90.78	103.49	109.38	113.34	105.77	131.81	161.12	111.12
Payable days	122.51	127.33	114.62	109.58	129.87	115.57	118.72	113.22	128.68	181.22	141.91
PER(x)	12.7	23.5	26.8	23.18	18.01	30.1	12.89	16.59	26.94	24.43	33.59
Price/Book(x)	3.71	6.65	6.35	4.69	3.27	4.06	1.85	3.24	2.29	1.68	3.24
Dividend Yield(%)	0.59	0.37	0.34	0.37	0.45	0.32	0.73	0.45	1.35	0.58	0.41
EV/Net Sales(x)	2.5	4.81	5.17	4.43	3.52	4.12	2.08	3.49	3.63	4.03	6.25
EV/Core EBITDA(x)	8.93	16.79	17.97	16.96	13.13	19.36	9.02	11.72	19.1	17.51	23.43
Net Sales Growth(%)	31.07	13.84	13.23	4.81	6.9	19.36	9.08	18.35	-28.67	-25.07	25.88
EBIT Growth(%)	122.37	14.61	14.7	-6.45	7.74	-8.36	19.03	61.54	-60.81	3.09	51.59
PAT Growth(%)	136.31	29.37	7.28	4.92	6.21	-15.61	22.69	65.86	-53.27	-14.61	52.97
EPS Growth(%)	136.07	29.15	7.06	4.8	6.21	-15.61	22.69	65.86	-53.27	-14.61	52.97
Debt/Equity(x)	0.73	0.61	0.61	0.36	0.37	0.4	0.29	0.25	0.11	0.23	0.14
Current Ratio(x)	1.53	1.61	1.45	1.55	1.56	1.55	1.77	1.83	2.35	1.47	1.35
Quick Ratio(x)	1.02	1.07	1	1.01	0.97	0.96	1.09	1.11	1.55	0.88	0.94
Interest Cover(x)	6.26	15.68	10.37	49.24	45.3	9.51	10.74	147.2	97.66	22.87	14.16
Total Debt/Mcap(x)	0.2	0.09	0.1	0.08	0.11	0.1	0.15	0.08	0.05	0.14	0.04

Aurobindo Pharma Shareholding Pattern

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	51.83	51.83	51.83	51.83	51.83	51.83	51.83	51.83	51.8	51.82
FII	20.71	21.4	22.31	23.02	24.13	22.45	20.72	18.02	16.73	16.59
DII	17.3	16.57	14.9	15.09	15.73	18.29	20.6	23.28	24.77	25.13
Public	10.15	10.2	10.96	10.05	8.31	7.42	6.85	6.87	6.7	6.46
Others	0	0	0	0	0	0	0	0	0	0
Total	100	100	100	100	100	100	100	100	100	100

#	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024
Promoter	30.37	30.37	30.37	30.37	30.37	30.37	30.37	30.37	30.35	30.09
FII	12.13	12.54	13.07	13.49	14.14	13.15	12.14	10.56	9.8	9.64
DII	10.14	9.71	8.73	8.84	9.22	10.72	12.07	13.64	14.51	14.6
Public	5.95	5.98	6.42	5.89	4.87	4.35	4.01	4.03	3.92	3.75
Others	0	0	0	0	0	0	0	0	0	0
Total	58.59	58.59	58.59	58.59	58.59	58.59	58.59	58.59	58.59	58.08

Pros

Debtor days have improved from 181.22 to 141.91days.
Company is almost debt free.

Cons

Company has a low return on equity of 9% over the last 3 years.
Stock is trading at 3.7 times its book value.
The company has delivered a poor profit growth of 4% over past five years.

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Aurobindo Pharma News

IPO

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Companies	Open Date	Close Date	Issue Price	Cost of 1 Lot	GMP	Expected Listing	Listing Gain(%)	Listing Price	Current Price	Type	Exchange

Aurobindo Pharma

Add Watchlist

Aurobindo Pharma Research see more...

Overview Inc. Year: 1986Industry: Pharmaceuticals & Drugs

Aurobindo Pharma Share Price

Alert Data

Quarterly Price

Peer Comparison

Aurobindo Pharma Quarterly Results

Aurobindo Pharma Profit & Loss

Growth Rates

Aurobindo Pharma Balance Sheet

Aurobindo Pharma Cash Flow

Aurobindo Pharma Ratios

Aurobindo Pharma Shareholding Pattern

Aurobindo Pharma News

IPO

Stocx: India's #1 Marketplace to Find Your Winning Stock

Please Login!

Error!